This single-blind, phase II trial (n=30) will assess the safety and efficacy of psilocybin-assisted psychotherapy for treatment-resistant anorexia nervosa in adults.
Status: Not yet recruiting
Start date: 2023-07-01
Phase II
Blinded
30 participants
Interventional
This second trial of COMP360 (psilocybin) by COMPASS will investigate the effectiveness of the psychedelic for anorexia in 60 patients.
Status: Not yet recruiting
Start date: 2022-08-01
Phase II
Blinded
60 participants
Interventional
To better understand the potential benefits of psychedelics in overeating disorders, Tryp Therapeutics will conduct a safety and feasibility clinical trial using TRP 8802 (psilocybin) among individuals with Binge Eating Disorder.
Status: Not yet recruiting
Start date: 2022-10-03
Open
10 participants
Interventional
This is a single-center phase 2a open-label study to assess the efficacy and safety of a dose of psilocybin in subjects with hyperphagia resulting in overeating during both dosing sessions
Status: Not yet recruiting
Start date: 2021-10-11
Phase II
Open
10 participants
Interventional
The investigators will also assess a number of exploratory measures related to eating disorder pathophysiology.
Status: Active, not recruiting
Start date: 2019-08-26
Phase I
Open
18 participants
Interventional
This Phase 2, open-label, multi-site study will explore the safety and feasibility of MDMA-assisted psychotherapy and adjunctive caregiver involvement in the treatment of 18 participants with eating disorders.
Status: Not yet recruiting
Start date: 2023-6-1
Phase II
Open
36 participants
Interventional
The primary aim of this study is to assess the acceptability and efficacy of treating anorexia nervosa with psilocybin. The secondary aim of this study is to use Magnetic Resonance Imaging (MRI) and Electroencephalography (EEG) to examine the neuronal underpinnings of treatment with psilocybin in this patient group.
Status: Recruiting
Start date: 2021-5-1
Phase I
Open
20 participants
Interventional
The primary aim of this study is to assess the safety and tolerability of one 25 mg dose of psilocybin in participants with anorexia nervosa based on adverse events (AEs), changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests. The secondary objectives are to explore the efficacy of a single 25 mg dose of psilocybin on eating disorder symptoms and behaviors, body image, anxiety, food related obsessions and rituals, and body weight.
Status: Completed
Start date: 2021-5-1
Phase II
Open
16 participants
Interventional
Find Psychedelic Trials
Browse through all psychedelic trials that have been done or are ongoing. These trials, usually double-blind, placebo-controlled studies, are the core of psychedelic research. The outcome of these trials will determine the future of psychedelics as medicine.
The trials included in our database come from ClinicalTrials.Gov and from the various companies pursuing psychedelics as medicine. Most of the trials have been funded by universities, though companies and governments are currently starting to ramp up their involvement.
